155 related articles for article (PubMed ID: 26088190)
1. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant.
Modesto W; Dal Ava N; Monteiro I; Bahamondes L
Arch Gynecol Obstet; 2015 Dec; 292(6):1387-91. PubMed ID: 26088190
[TBL] [Abstract][Full Text] [Related]
2. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
3. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
Bahamondes L; Brache V; Ali M; Habib N;
Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
[TBL] [Abstract][Full Text] [Related]
4. Female sexual function in women using LARC methods.
Trigo ACM; Maron CC; Pinheiro MSA; da Silva SBL; Brito MB
Gynecol Endocrinol; 2022 Jan; 38(1):68-72. PubMed ID: 34672861
[TBL] [Abstract][Full Text] [Related]
5. Changes in body composition in women using long-acting reversible contraception.
Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
[TBL] [Abstract][Full Text] [Related]
6. Weight change at 12 months in users of three progestin-only contraceptive methods.
Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
[TBL] [Abstract][Full Text] [Related]
7. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
Modesto W; Bahamondes MV; Bahamondes L
Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate.
Modesto W; Bahamondes MV; Bahamondes L
J Womens Health (Larchmt); 2015 Aug; 24(8):636-40. PubMed ID: 26098552
[TBL] [Abstract][Full Text] [Related]
9. Does Obesity Influence Body Mass Index Changes in Nulliparous Adolescent Users of Long-Acting Reversible Contraceptives?
Scott N; Silver EJ; Dodson NA; Coupey SM
J Pediatr Adolesc Gynecol; 2021 Dec; 34(6):815-820. PubMed ID: 34389461
[TBL] [Abstract][Full Text] [Related]
10. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
[TBL] [Abstract][Full Text] [Related]
12. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
13. Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism.
Di X; Li Y; Zhang C; Jiang J; Gu S
Contraception; 1999 Sep; 60(3):161-6. PubMed ID: 10640160
[TBL] [Abstract][Full Text] [Related]
14. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
[TBL] [Abstract][Full Text] [Related]
15. Body weight and body composition of depot medroxyprogesterone acetate users.
Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
[TBL] [Abstract][Full Text] [Related]
16. A multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonorgestrel contraceptive implants with nonrandomized copper-IUD controls: methodology and insertion data.
Meirik O; Brache V; Orawan K; Habib NA; Schmidt J; Ortayli N; Culwell K; Jackson E; Ali M;
Contraception; 2013 Jan; 87(1):113-20. PubMed ID: 23063337
[TBL] [Abstract][Full Text] [Related]
17. Impact of etonogestrel-releasing implant and copper intrauterine device on carbohydrate metabolism: a comparative study.
Oderich CL; Wender MC; Lubianca JN; Santos LM; de Mello GC
Contraception; 2012 Feb; 85(2):173-6. PubMed ID: 22067787
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception.
Beerthuizen R; van Beek A; Massai R; Mäkäräinen L; Hout J; Bennink HC
Hum Reprod; 2000 Jan; 15(1):118-22. PubMed ID: 10611199
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants.
Bahamondes L; Monteiro-Dantas C; Espejo-Arce X; Dos Santos Fernandes AM; Lui-Filho JF; Perrotti M; Petta CA
Hum Reprod; 2006 Feb; 21(2):466-70. PubMed ID: 16253974
[TBL] [Abstract][Full Text] [Related]
20. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration.
McNicholas C; Maddipati R; Zhao Q; Swor E; Peipert JF
Obstet Gynecol; 2015 Mar; 125(3):599-604. PubMed ID: 25730221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
